SABS

#3199
SAB Biotherapeutics, Inc. - Common Stock
3.7 7 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.76
3.77
Intervallo Annuale
1.85
5.15
Variazione giornaliera
-0.53%
Variazione Mensile
+5.01%
Variazione di 6 mesi
-4.31%
Variazione Annuale
+83.01%
Chiusura Precedente
3.7 9
Open
3.7 7
Minimo
3.7 6
Massimo
3.7 7
Volume
15
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
SAB Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SAB Biotherapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SAB Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SAB Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SAB Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
SAB Biotherapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
SAB Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
SAB Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
SAB Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
SAB Biotherapeutics, Inc. current report, Q1 FY2026
8-K

SAB Biotherapeutics, Inc. current report, Q1 FY2026

Full document

SAB Biotherapeutics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by SAB Biotherapeutics, Inc. (SABS) on January 7, 2026, covering events occurring on January 5, 2026. The filing primarily addresses changes to the Company's Board of Directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance rather than financial performance.

Material Changes

  • Board Appointments: The Board appointed David Zaccardelli, Pharm.D., and Rita Jain, M.D., as Class II directors, effective January 5, 2026.
  • Leadership Transition: Dr. Zaccardelli was appointed Chairperson of the Board. Samuel J. Reich, the Chief Executive Officer and former Chairperson, will continue to serve as a Board member.
  • Investor Nomination: The appointments were made pursuant to a letter agreement with RA Capital Healthcare Fund, L.P., following a private placement of securities in July 2025, which granted RA Capital the right to nominate up to two directors.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, outlook, or specific risk factors. It notes that the new directors will receive compensation similar to other non-employee Board members as described in the Company's 2024 Annual Report on Form 10-K. The Company entered into customary indemnity agreements with the new directors.

Key Facts for Investor Verification

  • Verify the terms of the July 21, 2025, letter agreement with RA Capital Healthcare Fund regarding board nomination rights.
  • Review the 2024 Annual Report on Form 10-K to confirm the compensation structure for non-employee directors.
  • Assess the strategic impact of Dr. Zaccardelli's background (former CEO of Verona Pharma and Dova Pharmaceuticals) and Dr. Jain's experience (former CMO at ChemoCentryx and Immunovant) on the Company's clinical development pipeline.
  • Confirm the status of the Company's cash position and runway, as this filing does not disclose current liquidity levels.

Notizie